FDA QMSR is in effect. What comes after implementation?
On January 31st, 2024, FDA released their final rule amending the Quality System Regulation (QSR) to better align with ISO 13485:2016, the international standard for quality management systems for medical devices. The final rule changes the title of 21 CFR Part 820 from the Quality System Regulation to the Quality Management System Regulation (QMSR)
Today, on February 2, 2026, the FDA’s Quality Management System Regulation (QMSR) officially came into effect. For many medical device manufacturers, the next steps were clear: gap analyses, updated procedures, revised design controls, and personnel training.
Those steps matter.
But under QMSR, they are no longer the end of the story.
From documentation to effectiveness
One of the most important changes under QMSR is a shift from paperwork to performance. Compliance is no longer demonstrated by the existence of procedures alone, but by evidence that the QMS consistently achieves its intended outcomes.
That’s why, in our QMSR checklist, all traditional implementation steps are marked as completed while effectiveness verification and ongoing monitoring remain intentionally open.
What effectiveness verification really means?
Effectiveness verification is not about proving that a procedure exists.
It is about demonstrating that the procedure achieves its intended outcome.
In practice, this may include:
- Trend analysis and KPIs
- Internal audit results over time
- CAPA effectiveness checks
- Feedback from post-market surveillance
- Management review inputs that lead to action
In other words: QMSR shifts the focus from documentation to evidence.
Inspection expectations are changing
This shift aligns closely with ISO 13485 thinking, but under QMSR it is no longer optional.
FDA inspections are now expected to focus less on whether something is written down and more on whether the system actually controls risk throughout the product lifecycle.
Center for Devices and Radiological Health (CDRH) Compliance Programs (Updated January 30, 2026)
As part of the QMSR transition, the FDA is retiring several long-standing inspection programs, effective February 2, 2026. These include Inspection of Medical Device Manufacturers (7382.845) and Medical Device PMA Preapproval and PMA Postmarket Inspections (7383.001).
The message is clear: inspections are no longer about following a predefined checklist, but about demonstrating that the quality system consistently controls risk and performs as intended.
In other words: the FDA’s own compliance framework is now structured around QMSR expectations.
These and other CDRH compliance program documents are available on the FDA’s website: https://www.fda.gov/medical-devices/quality-and-compliance-medical-devices/center-devices-and-radiological-health-cdrh-compliance-programs
QMSR implementation is not a milestone to celebrate.
It is a baseline.
What matters now is how well the system performs tomorrow, next year, and in the next inspection.
How Nometech can support you
Are you still struggling with QMSR implementation? If QMSR implementation feels unclear, fragmented, or stuck between theory and practice, Nometech can help.
We support medical device manufacturers with QMSR alignment, training, and inspection preparation always with a focus on what actually works in practice.
Let’s continue the conversation!